Growing prevalence of autoimmune disease and the consequent rise in healthcare expenditure has prompted the introduction of favorable government initiatives undertaken by pertinent research and diagnostics organizations. According to the NIH autoimmune disease are ranked amongst top ten causes of women deaths in the U.S. Growing lab automation rates is also expected to boost market growth by equipping clinicians with the ability to conduct multiple tests simultaneously and rendering faster and precise results. Slow turnaround time associated with autoimmune disease diagnostic procedures coupled with the presence of few standardized tests catering to over 80 disease types are some factors encouraging laboratories to move towards automation. Furthermore, public awareness campaigns aimed at elevating awareness levels pertaining to disease diagnostics is expected to positively reinforce product usage rates over the next six years.
Global autoimmune disease diagnostics market, by product 2012 - 2020 (USD Million)
Product segments of autoimmune disease diagnostics analyzed in this study include systemic and localized autoimmune disease diagnostics. Localized disease diagnostics was the leading product segment in 2013. The presence of large procedure volumes and relatively higher (in comparison with systemic autoimmune diseases) patient awareness levels are some factors accounting for its large share. Moreover, high unmet patient needs present in localized autoimmune disease segments such as type I diabetes and multiple sclerosis is expected to drive segment growth during the forecast period.
Systemic autoimmune disease diagnostics majorly include disorders such as rheumatoid arthritis, Ankylosing Spondylitis, and systemic lupus erythematosus (SLE). Rheumatoid arthritis held the largest share of the systemic autoimmune disease diagnostics market. Rheumatoid arthritis is one of the most frequently diagnosed autoimmune systemic inflammatory disorders, with a worldwide prevalence rate of around 1%. Onset can occur at any age mostly after 30 which may rise to disability after 10 years of diagnosis. The involvement of expensive organ assessment tests and the presence of high prevalence levels are some factors accounting for its large share. The presence of large volume of diagnostic tests and the introduction of new products such as drug based diagnostics are also expected to serve this segment as drivers.
Key regional segments of the autoimmune disease diagnostics market include North America, Europe, Asia-Pacific and RoW. North America was the largest market in 2013 owing to growing prevalence of autoimmune disorders, presence of sophisticated healthcare infrastructure and the presence of favorable government initiatives such as Affordable Care Act and Patient Protection Act. According to NIH estimates the annual expenditure of the U.S. on autoimmune disease diagnostics and therapeutics in nearly USD 100 billion. An increasing number of initiatives aimed at curbing healthcare expenditure pertaining to autoimmune disease therapeutics and diagnostics is expected to serve the market with enormous growth opportunities during the next six years.
Europe was the second largest market in 2013. Increasing government funding aimed at improving healthcare infrastructure and curbing autoimmune disease prevalence in the region is expected to positively reinforce the market. Growing prevalence of autoimmune diseases, the introduction of technological advancements such as portable diagnostic equipment and novel biomarkers are expected to drive regional market growth during the forecast period. The presence of large untapped opportunities available in the emerging Eastern European countries is expected to fuel the future growth of this market.
Industry rivalry levels for the autoimmune disease diagnostics market are expected to remain at a moderately high level during the forecast period. The market is consolidated in nature and is, therefore, marked by an extensive presence of mergers and acquisitions. These initiatives are expected to elevate competitive rivalry levels. Manufacturers face rigorous price based competition and are also under constant pressure to introduce new and technologically advanced products. Key players of the autoimmune disease diagnostics market include Roche Diagnostics, Abbott Laboratories, Siemens Healthcare, Beckman Coulter Inc., Euroimmun, SQI Diagnostics, INOVA Diagnostics Inc., AESKU Diagnostics, bioMerieux SA, Crescendo Bioscience, Hemagen Diagnostics, Bio-Rad and Quest Diagnostics.
Grand View Research offers special pricing for:
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.